Clinical Trials Logo

Advanced Colorectal Cancer clinical trials

View clinical trials related to Advanced Colorectal Cancer.

Filter by:

NCT ID: NCT04929652 Recruiting - Clinical trials for Advanced Colorectal Cancer

Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer

Start date: June 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The objective is to investigate the efficacy and safety of Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer.

NCT ID: NCT04764006 Recruiting - Clinical trials for Advanced Colorectal Cancer

Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study

Start date: October 13, 2021
Phase: Phase 2
Study type: Interventional

A phase II study to assess the efficacy and safety of Surufatinib combined with Sintilimab as a second-line treatment in patients with advanced MSS-Type CRC.

NCT ID: NCT04337879 Recruiting - Clinical trials for Advanced Colorectal Cancer

A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer

Start date: July 20, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study to explore the safety, tolerance and efficacy of AL2846 capsules combined with mFOLFOLX6 or FOLFIRI standard chemotherapy regimen in subjects with advanced metastatic colorectal cancer.

NCT ID: NCT04324476 Recruiting - Clinical trials for Advanced Colorectal Cancer

A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer

Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

The objective is to investigate the efficacy and safety of two-weekly alternative regimen of Bevacizumab plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer.

NCT ID: NCT04252456 Recruiting - Clinical trials for Advanced Colorectal Cancer

Folfiri/aflIbercept in Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status

DISTINCTIVE
Start date: April 23, 2018
Phase: N/A
Study type: Interventional

The study will a be a biologically enriched, prospectively stratified phase II trial in RAS wild type metastatic colorectal cancer patients progressing after first-line treatment with oxaliplatin, fluoropyrimidines and an anti-EGFR monoclonal antibody. All patients will receive aflibercept in combination with FOLFIRI according to the Italian label.

NCT ID: NCT03126071 Recruiting - Clinical trials for Advanced Colorectal Cancer

Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

Start date: February 15, 2017
Phase: Phase 2
Study type: Interventional

The objective is to investigate the efficacy and safety of raltitrexed-based chemotherapy plus bevacizumab in the treatment of advanced colorectal cancer

NCT ID: NCT00972465 Recruiting - Clinical trials for Advanced Colorectal Cancer

Study of Nimotuzumab to Treat Colorectal Cancer

Start date: June 2009
Phase: Phase 2
Study type: Interventional

Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The study assessed the safety, and efficacy of the combination of Nimotuzumab administered concomitantly with chemotherapy in patients with advanced colorectal cancer.

NCT ID: NCT00853684 Recruiting - Clinical trials for Advanced Colorectal Cancer

Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer

OXCE
Start date: February 2009
Phase: Phase 2
Study type: Interventional

It is hypothesized that other anti-angiogenic agents such as endostar, may augment the effect of chemotherapy regimens in CRC. Endostar, a recombinant human endostatin which expressed and purified in E. coli, was approved by the SFDA for the treatment of non-small-cell lung cancer in 2005. Ling et al. found that endostar suppressed the VEGF-stimulated proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro, and the antiangiogenic effects of endostar were correlated with the VEGF-triggered signaling. (Ling et al, 2007) A Chinese phase III clinical trial in advanced non-small-cell lung cancer, endostar--a new angiogenesis inhibitor prolonged the overall survival, time to progression and improved response rate. (Wang et al, 2005) Based on these results, the investigators design this phase II clinical trial of oxaliplatin, capecitabine and endostar as first line treatment, to evaluate whether endostar can bring survival benefits to patients with advanced colorectal cancer.